Shunsuke Inoguchi

Prognostic significance of the FAN score in patients with advanced urothelial carcinoma treated with enfortumab vedotin monotherapy

Hiromu Horitani, Atsunari Kawashima, Yu Ishizuya, Yoshiyuki Yamamoto et autres

OBJECTIVE: To evaluate the prognostic significance of the Fib-4 index, ALBI and NLR (FAN) score, a composite score comprising the fibrosis-4 index, albumin-bilirubin score, and neutrophil-to-lymphocyte ratio, in patients with advanced urothelial carcinoma treated with enfortumab vedotin (EV) monotherapy. METHODS: This multicenter …

jp (code pays fourni par la source)

Perioperative safety and oncological outcomes of robot-assisted radical cystectomy in patients aged ≥80 years: A propensity score-matched multi-institutional study

Shunsuke Inoguchi, Atsunari Kawashima, Yu Ishizuya, Takuji Hayashi et autres

This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.This version will undergo additional copyediting,

jp (code pays fourni par la source)

Short-term efficacy and safety of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma regardless of cisplatin eligibility

Takuji Hayashi, Atsunari Kawashima, Yoshiyuki Yamamoto, Yu Ishizuya et autres

OBJECTIVE: This study aimed to evaluate the short-term efficacy and safety of enfortumab vedotin plus pembrolizumab (EV + P) as a first-line systemic therapy for patients with advanced urothelial carcinoma (UC) in real-world practice, with a focus on cisplatin (CDDP) eligibility. METHODS: …

jp (code pays fourni par la source)

Peripheral B-cell receptor repertoire predicts immune-related adverse events following immune checkpoint inhibitor therapy in advanced renal cell carcinoma

Akihiro Yoshimura, Taigo Kato, Yasutomo Nakai, Masashi Nakayama et autres

Immune checkpoint inhibitor (ICI) combination therapy is effective for metastatic renal cell carcinoma (mRCC), but immune-related adverse events (irAEs) remain unpredictable. We analyzed peripheral B-cell receptor (BCR) repertoires in patients with mRCC before and 1 month after ICI initiation. BCR complementarity-determining region …

jp (code pays fourni par la source)

Microbiome–Driven Carcinogenesis and Circulating Microbial Signals in Genitourinary Cancers

Atsunari Kawashima, Kentaro Jingushi, Takuro Saito, Toshihiro Uemura et autres

The microbiome is increasingly recognized as a regulator of carcinogenesis, tumor immunity, and response to immune checkpoint inhibitors (ICIs), but its role in genitourinary cancers remains less clearly defined than in melanoma or colorectal cancer. In this review, we summarize evidence that …

jp (code pays fourni par la source)

Myosteatosis Predicts Poor Prognosis in Patients With Castration‐Resistant Prostate Cancer Treated With Enzalutamide

Tomohiro Kanaki, Koji Hatano, Toshiki Oka, Masaru Tani et autres

OBJECTIVES: Prostate cancer prognostication has traditionally emphasized tumor-related factors (e.g., Gleason score and metastatic burden). Emerging evidence suggests that physical (host) factors influence outcomes. This study evaluated whether physical factors, including myosteatosis and sarcopenia, are prognostic factors in patients with androgen receptor …

jp (code pays fourni par la source)

PD21-04 COMPOUND LIBRARY SCREENING IDENTIFIED NOVEL RADIOSENSITIZERS FOR PROSTATE CANCER

Koji Hatano, Toshiki Oka, Shohei Katsuki, Tomohiro Kanaki et autres

GG02-40 EXERCISE INHIBITS PROSTATE CANCER PROGRESSION BY SUPPRESSING ARGINASE1

Toshiki Oka, Koji Hatano, Hiroaki Hase, Masatoshi Konishi et autres

IP83-26 REAL-WORLD TREATMENT PATTERNS AND SURVIVAL OUTCOMES IN METASTATIC UROTHELIAL CARCINOMA IN THE ENFORTUMAB VEDOTIN ERA: IMPACT OF FIRST-LINE ENFORTUMAB VEDOTIN PLUS PEMBROLIZUMAB VERSUS PLATINUM CHEMOTHERAPY

Atsunari Kawashima, Takeshi Ujike, Yujiro Hayashi, Ayuko Higaki et autres

Short-term outcomes of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: Real-world use in multicenter cohort regardless of cisplatin eligibility

Takuji Hayashi, Atsunari Kawashima, Yoshiyuki Yamamoto, Yu Ishizuya et autres

jp (code pays fourni par la source)

Root-localized aortic dissection in Loeys–Dietz syndrome diagnosed with the coronary computed tomography angiography: a case report

Ikumi Inoue, Shunsuke Inoguchi, Yasushi Ino, Keizo Kimura et autres

Background: Aortic dissection is caused by a tear in the inner layer of the aorta, and blood comes between the layers of the aortic wall. Contrast-enhanced computed tomography (CT) is typically considered to be useful in its diagnosis. However, in cases of …

jp (code pays fourni par la source)

Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer

Toshiki Oka, Koji Hatano, Shohei Katsuki, Tomohiro Kanaki et autres

Radiation therapy effectively treats prostate cancer, but tumor recurrence remains a clinical challenge, highlighting the need for strategies to enhance radiosensitivity. In this study, we developed a simple, high-throughput drug repurposing screening platform to find radiosensitizers from compounds approved by the U.S. …

jp, us (code pays fourni par la source)